Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients

Kunchok Dorjee, Hyunju Kim, Elizabeth Bonomo and 1 more

PLOS ONE · 2020 · Meta-analysis · CC BY

doi:10.1371/journal.pone.0243191

Abstract

Introduction. Progression of COVID-19 to severe disease and death is insufficiently understood.

Objective. Summarize the prevalence of risk factors and adverse outcomes and determine their associations in COVID-19 patients who were hospitalized.

Methods. We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19 patients through August 31, 2020. Data were analyzed by fixed-effects meta-analysis using Shore’s adjusted confidence intervals to address heterogeneity.

Results. Seventy-seven studies comprising 38906 hospitalized patients met inclusion criteria; 21468 from the US-Europe and 9740 from China. Overall prevalence of death [% (95% CI)] from COVID-19 was 20% (18–23%); 23% (19–27%) in the US and Europe and 11% (7–16%) for China. Of those that died, 85% were aged≥60 years, 66% were males, and 66%, 44%, 39%, 37%, and 27% had hypertension, smoking history, diabetes, heart disease, and chronic kidney disease (CKD), respectively. The case fatality risk [%(95% CI)] were 52% (46–60) for heart disease, 51% (43–59) for COPD, 48% (37–63) for chronic kidney disease (CKD), 39% for chronic liver disease (CLD), 28% (23–36%) for hypertension, and 24% (17–33%) for diabetes. Summary relative risk (sRR) of death were higher for age≥60 years [sRR = 3.6; 95% CI: 3.0–4.4], males [1.3; 1.2–1.4], smoking history [1.3; 1.1–1.6], COPD [1.7; 1.4–2.0], hypertension [1.8; 1.6–2.0], diabetes [1.5; 1.4–1.7], heart disease [2.1; 1.8–2.4], CKD [2.5; 2.1–3.0]. The prevalence of hypertension (55%), diabetes (33%), smoking history (23%) and heart disease (17%) among the COVID-19 hospitalized patients in the US were substantially higher than that of the general US population, suggesting increased susceptibility to infection or disease progression for the individuals with comorbidities.

Conclusions. Public health screening for COVID-19 can be prioritized based on risk-groups. Appropriately addressing the modifiable risk factors such as smoking, hypertension, and diabetes could reduce morbidity and mortality due to COVID-19; public messaging can be accordingly adapted.

References 121

  1. 1.

    Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Published 2020. Accessed October 8, 2020.

    Not in our library

  2. 2.
    Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 · 2020
    No notice
  3. 3.

    Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020:

    Not in our library10.1001/jama.2020.2648

  4. 4.

    Cummings MJ, Baldwin MR, Abrams D, et al Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770.

    Not in our library10.1016/s0140-6736(20)31189-2

  5. 5.

    Du RH, Liang LR, Yang CQ, et al Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5).

    Not in our library10.1183/13993003.00524-2020

  6. 6.

    Li X, Xu S, Yu M, et al Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118.

    Not in our library10.1016/j.jaci.2020.04.006

  7. 7.

    Palaiodimos L, Kokkinidis DG, Li W, et al Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262

    Not in our library10.1016/j.metabol.2020.154262

  8. 8.

    Wu C, Chen X, Cai Y, et al Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.

    Not in our library10.1001/jamainternmed.2020.0994

  9. 9.
    Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis · 2020
    No notice
  10. 10.

    Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107–108.

    Not in our library10.1016/j.ejim.2020.03.014

  11. 11.

    Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine Tob Res. 2020;22(9):1653–1656.

    Not in our library10.1093/ntr/ntaa082

  12. 12.

    Rossato M, Russo L, Mazzocut S, Di Vincenzo A, Fioretto P, Vettor R. Current smoking is not associated with COVID-19. Eur Respir J. 2020;55(6).

    Not in our library10.1183/13993003.01290-2020

  13. 13.

    Guan WJ, Liang WH, Zhao Y, et al Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5).

    Not in our library10.1183/13993003.00547-2020

  14. 14.

    Zhou F, Yu T, Du R, et al Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.

    Not in our library10.1016/s0140-6736(20)30566-3

  15. 15.

    Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020;126(10):1443–1455.

    Not in our library10.1161/circresaha.120.317055

  16. 16.

    Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373–374.

    Not in our library10.1093/ajh/hpaa057

  17. 17.

    Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260.

    Not in our library10.1038/s41569-020-0360-5

  18. 18.

    Li X, Guan B, Su T, et al Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart. 2020;106(15):1142–1147.

    Not in our library10.1136/heartjnl-2020-317062

  19. 19.

    Yang J, Zheng Y, Gou X, et al Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.

    Not in our library10.1016/j.ijid.2020.03.017

  20. 20.

    Zheng Z, Peng F, Xu B, et al Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25.

    Not in our library10.1016/j.jinf.2020.04.021

  21. 21.

    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.

    Not in our library10.1016/0197-2456(86)90046-2

  22. 22.

    Cochran WG. The Combination of Estimates From Different Experiments. Biometrics. 1954;10(1):101–129.

    Not in our library

  23. 23.

    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.

    Not in our library10.1002/sim.1186

  24. 24.

    Shore RE, Gardner MJ, Pannett B. Ethylene oxide: an assessment of the epidemiological evidence on carcinogenicity. Br J Ind Med. 1993;50(11):971–997.

    Not in our library10.1136/oem.50.11.971

  25. 25.

    Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis. 2020;7(2):91–96.

    Not in our library10.1515/dx-2020-0046

  26. 26.

    Argenziano MG, Bruce SL, Slater CL, et al Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. Bmj. 2020;369:m1996

    Not in our library10.1136/bmj.m1996

  27. 27.

    Brill SE, Jarvis HC, Ozcan E, et al COVID-19: a retrospective cohort study with focus on the over-80s and hospital-onset disease. BMC Med. 2020;18(1):194

    Not in our library10.1186/s12916-020-01665-z

  28. 28.

    Cao Z, Li T, Liang L, et al Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. PLoS One. 2020;15(6):e0234764

    Not in our library10.1371/journal.pone.0234764

  29. 29.

    Chen G, Wu D, Guo W, et al Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.

    Not in our library10.1172/jci137244

  30. 30.

    Chen J, Qi T, Liu L, et al Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1–e6.

    Not in our library10.1016/j.jinf.2020.03.004

  31. 31.
    Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China · 2020
    No notice
  32. 32.

    Chen T, Wu D, Chen H, et al Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091–m1091.

    Not in our library10.1136/bmj.m1091

  33. 33.

    Chilimuri S, Sun H, Alemam A, et al Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City. West J Emerg Med. 2020;21(4):779–784.

    Not in our library10.5811/westjem.2020.6.47919

  34. 34.

    Ciceri F, Castagna A, Rovere-Querini P, et al Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020;217:108509

    Not in our library10.1016/j.clim.2020.108509

  35. 35.

    Deng Y, Liu W, Liu K, et al Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133(11):1261–1267.

    Not in our library10.1097/cm9.0000000000000824

  36. 36.

    Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, et al Risk factors for mortality in patients with Coronavirus Disease 2019 (COVID-19) in Bolivia: An analysis of the first 107 confirmed cases. Infez Med. 2020;28(2):238–242.

    Not in our library

  37. 37.

    Feng Y, Ling Y, Bai T, et al COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380–1388.

    Not in our library10.1164/rccm.202002-0445oc

  38. 38.

    Ferguson J, Rosser JI, Quintero O, et al Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020. Emerg Infect Dis. 2020;26(8).

    Not in our library10.3201/eid2608.201776

  39. 39.

    Galloway JB, Norton S, Barker RD, et al A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. J Infect. 2020;81(2):282–288.

    Not in our library10.1016/j.jinf.2020.05.064

  40. 40.

    Garibaldi BT, Fiksel J, Muschelli J, et al Patient Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study. Ann Intern Med. 2020

    Not in our library10.7326/m20-3905

All 121 references

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.